Brittany Trang, Ph.D., covers AI in health and medicine: Does it actually work? Who benefits, or might be harmed? She writes the weekly AI Prognosis newsletter. Follow her on Threads, Mastodon, and Bluesky. You can reach Brittany on Signal at btrang.01.At first, Pfizer’s offer to buy obesity startup Metsera was $7.3 billion. Then Novo Nordisk entered the fray with an unsolicited bid for $9 billion. Then it was a $10 billion counteroffer. A bidding war like that is an investor’s dream, and it happened to Clive Meanwell. Now, he’s betting on AI to help him do it again.
The onetime oncologist has worked in drug development and biotech investment for close to four decades, and he’s now investing in big ideas with firm Population Health Partners, where he’s chairman and partner.
The firm looks for the biggest problems facing human health, problems that could yield a handsome return on investment when solved. “Then we ask the question, ‘Is there anywhere in the world a technology, or a new business model, or a molecule or two or three, or a class of drugs or diagnostics that could solve this problem?’” he said.
STAT+ Exclusive Story
Already have an account? Log in
